ZOLEDRONIC ACID injection, solution, concentrate

Country: Сједињене Америчке Државе

Језик: Енглески

Извор: NLM (National Library of Medicine)

Активни састојак:

ZOLEDRONIC ACID (UNII: 6XC1PAD3KF) (ZOLEDRONIC ACID ANHYDROUS - UNII:70HZ18PH24)

Доступно од:

AuroMedics Pharma LLC

INN (Међународно име):

ZOLEDRONIC ACID

Састав:

ZOLEDRONIC ACID ANHYDROUS 4 mg in 5 mL

Пут администрације:

INTRAVENOUS

Тип рецептора:

PRESCRIPTION DRUG

Терапеутске индикације:

Zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cCa) of greater than or equal to 12 mg/dL [3.0 mmol/L] using the formula: cCa in mg/dL = Ca in mg/dL + 0.8 (4.0 g/dL - patient albumin [g/dL]). Zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. Limitations of Use The safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non−tumor-related conditions have not been established. Hypersensitivity to Zoledronic Acid or Any Components of Zoledronic Acid Injection Hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been

Резиме производа:

Zoledronic acid injection is a sterile clear, colorless liquid solution for dilution prior to intravenous infusion and is supplied as follows: 4 mg per 5 mL (0.8 mg / mL) single-dose vial for dilution prior to intravenous infusion    5 mL Single-Dose Vials    Packaged Individually                                                     NDC 55150-266-05 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Discard unused portion. The vial stoppers are not made with natural rubber latex.

Статус ауторизације:

Abbreviated New Drug Application

Карактеристике производа

ZOLEDRONIC ACID - ZOLEDRONIC ACID INJECTION, SOLUTION, CONCENTRATE
AUROMEDICS PHARMA LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
ZOLEDRONIC ACID
INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
ZOLEDRONIC ACID
INJECTION.
ZOLEDRONIC ACID INJECTION, FOR INTRAVENOUS USE
INITIAL U.S. APPROVAL: 2001
INDICATIONS AND USAGE
Zoledronic acid injection is a bisphosphonate indicated for the
treatment of:
Hypercalcemia of malignancy (1.1)
Patients with multiple myeloma and patients with documented bone
metastases from solid tumors, in
conjunction with standard antineoplastic therapy. Prostate cancer
should have progressed after
treatment with at least one hormonal therapy. (1.2)
Limitations of Use: The safety and efficacy of zoledronic acid
injection has not been established for use in
hyperparathyroidism or non-tumor-related hypercalcemia.
DOSAGE AND ADMINISTRATION
Hypercalcemia of Malignancy (2.1)
4 mg as a single-dose intravenous infusion over no less than 15
minutes.
4 mg as retreatment after a minimum of 7 days.
Multiple myeloma and Bone Metastasis of Solid Tumors (2.2)
4 mg as a single-dose intravenous infusion over no less than 15
minutes every 3 to 4 weeks for
patients with creatinine clearance of greater than 60 mL/min.
Reduce the dose for patients with renal impairment.
Coadminister oral calcium supplements of 500 mg and a multiple vitamin
containing 400 international
units of vitamin D daily.
Administer through a separate vented infusion line and do not allow to
come in contact with any calcium or
divalent cation-containing solutions. (2.3)
DOSAGE FORMS AND STRENGTHS
Injection: 4 mg per 5 mL (0.8 mg/mL) single-dose vial for dilution
prior to intravenous infusion (3)
CONTRAINDICATIONS
Hypersensitivity to any component of zoledronic acid injection (4)
WARNINGS AND PRECAUTIONS
Patients being treated with zoledronic acid should not be treated with
Reclast
. (5.1)
Adequately rehydrate patients with hypercalcemia of malignanc